{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:16:25Z","timestamp":1783163785797,"version":"3.54.6"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40261-025-01520-0","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:15:01Z","timestamp":1780060501000},"page":"701-720","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current Strategies and Emerging Paradigms of Immunotherapy in Microsatellite Stable Colorectal Cancer: A Review Article"],"prefix":"10.1007","volume":"46","author":[{"given":"Lu-Ying","family":"Zhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"3","key":"1520_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"1520_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18061324","author":"A Passardi","year":"2017","unstructured":"Passardi A, Canale M, Valgiusti M, Ulivi P. Immune checkpoints as a target for colorectal cancer treatment. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18061324.","journal-title":"Int J Mol Sci"},{"key":"1520_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18010197","author":"I M\u00e1rmol","year":"2017","unstructured":"M\u00e1rmol I, S\u00e1nchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18010197.","journal-title":"Int J Mol Sci"},{"key":"1520_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02039","volume":"11","author":"A Lin","year":"2020","unstructured":"Lin A, Zhang J, Luo P. Crosstalk between the MSI status and tumor microenvironment in colorectal cancer. Front Immunol. 2020;11:2039. https:\/\/doi.org\/10.3389\/fimmu.2020.02039.","journal-title":"Front Immunol"},{"issue":"20","key":"1520_CR5","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1056\/NEJMc1510353","volume":"373","author":"Y Asaoka","year":"2015","unstructured":"Asaoka Y, Ijichi H, Koike K. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;373(20):1979. https:\/\/doi.org\/10.1056\/NEJMc1510353.","journal-title":"N Engl J Med"},{"key":"1520_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002844","author":"A Stein","year":"2021","unstructured":"Stein A, Simnica D, Schulthei\u00df C, Scholz R, Tintelnot J, G\u00f6kkurt E, et al. PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-002844.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"1520_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103669","volume":"28","author":"M Al Zein","year":"2023","unstructured":"Al Zein M, Boukhdoud M, Shammaa H, Mouslem H, El Ayoubi LM, Iratni R, et al. Immunotherapy and immunoevasion of colorectal cancer. Drug Discov Today. 2023;28(9):103669. https:\/\/doi.org\/10.1016\/j.drudis.2023.103669.","journal-title":"Drug Discov Today"},{"issue":"1","key":"1520_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/jco.19.02107","volume":"38","author":"DT Le","year":"2020","unstructured":"Le DT, Kim TW, Van Cutsem E, Geva R, J\u00e4ger D, Hara H, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11\u20139. https:\/\/doi.org\/10.1200\/jco.19.02107.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1520_CR9","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Fanchi LF, Dijkstra KK, den Van Berg JG, Aalbers AG, Sikorska K, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566\u201376. https:\/\/doi.org\/10.1038\/s41591-020-0805-8.","journal-title":"Nat Med"},{"issue":"6","key":"1520_CR10","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/jamaoncol.2020.0910","volume":"6","author":"EX Chen","year":"2020","unstructured":"Chen EX, Jonker DJ, Loree JM, Kennecke HF, Berry SR, Couture F, et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian Cancer Trials Group CO.26 study. JAMA Oncol. 2020;6(6):831\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0910.","journal-title":"JAMA Oncol"},{"issue":"9","key":"1520_CR11","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","volume":"30","author":"AJ Bullock","year":"2024","unstructured":"Bullock AJ, Schlechter BL, Fakih MG, Tsimberidou AM, Grossman JE, Gordon MS, et al. Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. Nat Med. 2024;30(9):2558\u201367. https:\/\/doi.org\/10.1038\/s41591-024-03083-7.","journal-title":"Nat Med"},{"issue":"6","key":"1520_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100639","volume":"7","author":"E Garralda","year":"2022","unstructured":"Garralda E, Sukari A, Lakhani NJ, Patnaik A, Lou Y, Im SA, et al. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. ESMO Open. 2022;7(6):100639. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100639.","journal-title":"ESMO Open"},{"issue":"7_Supplement","key":"1520_CR13","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2024-ct276","volume":"84","author":"H-J Lenz","year":"2024","unstructured":"Lenz H-J, Yuan Y, Li V, Zhang J, Jamal L, Lin X, et al. Abstract CT276: liberty-201: maintenance fluoropyrimidine (FP) and bevacizumab with or without anti-lymphocyte activation gene-3 (LAG-3) antibody LBL-007 plus anti-programmed cell death protein-1 (PD-1) antibody tislelizumab (TIS) for patients (pts) with metastatic or unresectable microsatellite stable (MSS)\/mismatch repair proficient (pMMR) colorectal cancer (CRC). Cancer Res. 2024;84(7_Supplement):CT276-CT. https:\/\/doi.org\/10.1158\/1538-7445.Am2024-ct276.","journal-title":"Cancer Res"},{"issue":"4_suppl","key":"1520_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.2022.40.4_suppl.008","volume":"40","author":"H-J Lenz","year":"2022","unstructured":"Lenz H-J, Parikh AR, Spigel DR, Cohn AL, Yoshino T, Kochenderfer MD, et al. Nivolumab (NIVO) + 5-fluorouracil\/leucovorin\/oxaliplatin (mFOLFOX6)\/bevacizumab (BEV) versus mFOLFOX6\/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8. J Clin Oncol. 2022;40(4_suppl):8. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.008.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1520_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07268-4","volume":"20","author":"A Damato","year":"2020","unstructured":"Damato A, Iachetta F, Antonuzzo L, Nasti G, Bergamo F, Bordonaro R, et al. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri\/bevacizumab in patients with advanced COlorectal cancer RAS or BRAF mutated\u2014NIVACOR trial (GOIRC-03-2018). BMC Cancer. 2020;20(1):822. https:\/\/doi.org\/10.1186\/s12885-020-07268-4.","journal-title":"BMC Cancer"},{"issue":"4","key":"1520_CR16","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/cam4.3630","volume":"10","author":"MR Patel","year":"2021","unstructured":"Patel MR, Falchook GS, Hamada K, Makris L, Bendell JC. A phase 2 trial of trifluridine\/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer. Cancer Med. 2021;10(4):1183\u201390. https:\/\/doi.org\/10.1002\/cam4.3630.","journal-title":"Cancer Med"},{"issue":"2","key":"1520_CR17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.clcc.2024.03.001","volume":"23","author":"R Kim","year":"2024","unstructured":"Kim R, Tehfe M, Kavan P, Chaves J, Kortmansky JS, Chen EX, et al. Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable\/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D. Clin Colorectal Cancer. 2024;23(2):118\u201327. https:\/\/doi.org\/10.1016\/j.clcc.2024.03.001. (e6).","journal-title":"Clin Colorectal Cancer"},{"key":"1520_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.993611","volume":"12","author":"J Tintelnot","year":"2022","unstructured":"Tintelnot J, Ristow I, Sauer M, Simnica D, Schulthei\u00df C, Scholz R, et al. Translational analysis and final efficacy of the AVETUX trial\u2014avelumab, cetuximab and FOLFOX in metastatic colorectal cancer. Front Oncol. 2022;12:993611. https:\/\/doi.org\/10.3389\/fonc.2022.993611.","journal-title":"Front Oncol"},{"issue":"2","key":"1520_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.49040","volume":"5","author":"NB Mettu","year":"2022","unstructured":"Mettu NB, Ou FS, Zemla TJ, Halfdanarson TR, Lenz HJ, Breakstone RA, et al. Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer: a randomized clinical trial. JAMA Netw Open. 2022;5(2):e2149040. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.49040.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"1520_CR20","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/s1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143\u201352. https:\/\/doi.org\/10.1016\/s1470-2045(17)30074-8.","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"1520_CR21","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1200\/JCO.2023.41.16_suppl.3500","volume":"41","author":"C Antoniotti","year":"2023","unstructured":"Antoniotti C, Rossini D, Pietrantonio F, Salvatore L, Marmorino F, Ambrosini M, et al. FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study. J Clin Oncol. 2023;41(16_suppl):3500. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.3500.","journal-title":"J Clin Oncol"},{"issue":"3_suppl","key":"1520_CR22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1200\/JCO.2024.42.3_suppl.124","volume":"42","author":"R-H Xu","year":"2024","unstructured":"Xu R-H, Wang F, Peng J, Liang X, Cheng Y, Deng Y, et al. First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2\/3 study. J Clin Oncol. 2024;42(3_suppl):124. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.124.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"1520_CR23","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1200\/JCO.2020.38.15_suppl.3006","volume":"38","author":"F Ghiringhelli","year":"2020","unstructured":"Ghiringhelli F, Chibaudel B, Taieb J, Bennouna J, Martin-Babau J, Fonck M, et al. Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable, previously untreated metastatic colorectal cancer (MCRC): Results of the first intermediate analysis of the phase Ib\/II MEDETREME trial. J Clin Oncol. 2020;38(15_suppl):3006. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.3006.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1520_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11139-z","volume":"23","author":"X Fang","year":"2023","unstructured":"Fang X, Zhong C, Weng S, Hu H, Wang J, Xiao Q, et al. Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study. BMC Cancer. 2023;23(1):676. https:\/\/doi.org\/10.1186\/s12885-023-11139-z.","journal-title":"BMC Cancer"},{"issue":"12","key":"1520_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7224","volume":"13","author":"F Pei","year":"2024","unstructured":"Pei F, He W, Duan Y, Yao Q, Zhao Y, Fan X, et al. PD-1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR\/MSS colorectal cancer. Cancer Med. 2024;13(12):e7224. https:\/\/doi.org\/10.1002\/cam4.7224.","journal-title":"Cancer Med"},{"key":"1520_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2022.03.026","volume":"169","author":"RD Kim","year":"2022","unstructured":"Kim RD, Kovari BP, Martinez M, Xie H, Sahin IH, Mehta R, et al. A phase I\/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Eur J Cancer. 2022;169:93\u2013102. https:\/\/doi.org\/10.1016\/j.ejca.2022.03.026.","journal-title":"Eur J Cancer"},{"issue":"5","key":"1520_CR27","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1001\/jamaoncol.2022.7845","volume":"9","author":"M Fakih","year":"2023","unstructured":"Fakih M, Sandhu J, Lim D, Li X, Li S, Wang C. Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized clinical trial. JAMA Oncol. 2023;9(5):627\u201334. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7845.","journal-title":"JAMA Oncol"},{"issue":"15_suppl","key":"1520_CR28","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1200\/JCO.2021.39.15_suppl.3560","volume":"39","author":"M Fakih","year":"2021","unstructured":"Fakih M, Raghav KPS, Chang DZ, Bendell JC, Larson T, Cohn AL, et al. Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)\/microsatellite stable (MSS) colorectal cancer (CRC). J Clin Oncol. 2021;39(15_suppl):3560. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.3560.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1520_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100383","volume":"2","author":"F Wang","year":"2021","unstructured":"Wang F, He MM, Yao YC, Zhao X, Wang ZQ, Jin Y, et al. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib\/II clinical trial and gut microbiome analysis. Cell Rep Med. 2021;2(9):100383. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100383.","journal-title":"Cell Rep Med"},{"key":"1520_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.561","volume":"33","author":"W Zhang","year":"2022","unstructured":"Zhang W, Sun Y, Jiang Z, Liu T, Gong C, Yang L, et al. 423P fruquintinib plus sintilimab in refractory repair-proficient (pMMR)\/microsatellite stable (MSS) metastatic colorectal cancer (mCRC): preliminary clinical results and biomarker analyses from a phase II study. Ann Oncol. 2022;33:S728. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.561.","journal-title":"Ann Oncol"},{"issue":"6","key":"1520_CR31","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2025.15287","volume":"30","author":"Y Peng","year":"2025","unstructured":"Peng Y, Li S, Zhu L. Efficacy and safety of fruquintinib combined with immunotherapy in later-line treatment of metastatic colorectal cancer. Oncol Lett. 2025;30(6):541. https:\/\/doi.org\/10.3892\/ol.2025.15287.","journal-title":"Oncol Lett"},{"issue":"4_suppl","key":"1520_CR32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1200\/JCO.2022.40.4_suppl.135","volume":"40","author":"A Saeed","year":"2022","unstructured":"Saeed A, Park R, Dai J, Al-Rajabi RMT, Kasi A, Saeed A, et al. Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients with advanced mismatch repair proficient\/microsatellite stable (pMMR\/MSS) colorectal cancer (CRC): CAMILLA CRC cohort results. J Clin Oncol. 2022;40(4_suppl):135. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.135.","journal-title":"J Clin Oncol"},{"key":"1520_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.877635","volume":"12","author":"J Lang","year":"2022","unstructured":"Lang J, Leal AD, Mar\u00edn-Jim\u00e9nez JA, Hartman SJ, Shulman J, Navarro NM, et al. Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models. Front Oncol. 2022;12:877635. https:\/\/doi.org\/10.3389\/fonc.2022.877635.","journal-title":"Front Oncol"},{"issue":"3_suppl","key":"1520_CR34","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1200\/JCO.2021.39.3_suppl.94","volume":"39","author":"C Gomez-Roca","year":"2021","unstructured":"Gomez-Roca C, Yanez E, Im S-A, Alvarez EC, Senellart H, Doherty M, et al. LEAP-005: a phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors\u2014results from the colorectal cancer cohort. J Clin Oncol. 2021;39(3_suppl):94. https:\/\/doi.org\/10.1200\/JCO.2021.39.3_suppl.94.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1520_CR35","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.clcc.2024.05.002","volume":"23","author":"A Hernando-Calvo","year":"2024","unstructured":"Hernando-Calvo A, Han M, Ayodele O, Wang BX, Bruce JP, Abbas-Aghababazadeh F, et al. A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer. Clin Colorectal Cancer. 2024;23(3):272\u201384. https:\/\/doi.org\/10.1016\/j.clcc.2024.05.002. (e9).","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"1520_CR36","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2159-8290.Cd-17-1226","volume":"8","author":"RB Corcoran","year":"2018","unstructured":"Corcoran RB, Andr\u00e9 T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov. 2018;8(4):428\u201343. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-1226.","journal-title":"Cancer Discov"},{"key":"1520_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","volume":"85","author":"R Ullah","year":"2022","unstructured":"Ullah R, Yin Q, Snell AH, Wan L. RAF-MEK-ERK pathway in cancer evolution and treatment. Semin Cancer Biol. 2022;85:123\u201354. https:\/\/doi.org\/10.1016\/j.semcancer.2021.05.010.","journal-title":"Semin Cancer Biol"},{"key":"1520_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21031102","author":"S Lee","year":"2020","unstructured":"Lee S, Rauch J, Kolch W. Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21031102.","journal-title":"Int J Mol Sci"},{"key":"1520_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.940523","volume":"12","author":"S Napolitano","year":"2022","unstructured":"Napolitano S, Martini G, Ciardiello D, Di Maio M, Normanno N, Avallone A, et al. CAVE-2 (cetuximab-avelumab) mCRC: a phase II randomized clinical study of the combination of avelumab plus cetuximab as a rechallenge strategy in pre-treated RAS\/BRAF wild-type mCRC patients. Front Oncol. 2022;12:940523. https:\/\/doi.org\/10.3389\/fonc.2022.940523.","journal-title":"Front Oncol"},{"issue":"3_suppl","key":"1520_CR40","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1200\/JCO.2021.39.3_suppl.80","volume":"39","author":"MVD Eynde","year":"2021","unstructured":"Eynde MVD, Huyghe N, Cuyper AD, Sinapi I, Ferrier M, Gilet M, et al. Interim analysis of the AVETUXIRI Trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)\u2014a proof of concept, open-label, nonrandomized phase IIa study. J Clin Oncol. 2021;39(3_suppl):80. https:\/\/doi.org\/10.1200\/JCO.2021.39.3_suppl.80.","journal-title":"J Clin Oncol"},{"key":"1520_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1815","author":"M Qiu","year":"2023","unstructured":"Qiu M, Wei G, Leng W-B, Cao P. 624P tolerability and safety of vemurafenib, cetuximab combined with camrelizumab for BRAF V600E-mutated \/MSS metastatic colorectal cancer. Ann Oncol. 2023. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1815.","journal-title":"Ann Oncol"},{"issue":"4_suppl","key":"1520_CR42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1200\/JCO.2022.40.4_suppl.012","volume":"40","author":"VK Morris","year":"2022","unstructured":"Morris VK, Parseghian CM, Escano M, Johnson B, Raghav KPS, Dasari A, et al. Phase I\/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer. J Clin Oncol. 2022;40(4_suppl):12. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.012.","journal-title":"J Clin Oncol"},{"key":"1520_CR43","doi-asserted-by":"publisher","first-page":"TPS265","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS265","volume":"41","author":"V Morris","year":"2023","unstructured":"Morris V, Guthrie K, Kopetz S, Breakstone R, Karasic T, Hu Z, et al. Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAF V600E metastatic and\/or unresectable colorectal cancer: SWOG S2107. J Clin Oncol. 2023;41:TPS265. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.TPS265.","journal-title":"J Clin Oncol"},{"key":"1520_CR44","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.coph.2015.05.012","volume":"23","author":"IE Templeton","year":"2015","unstructured":"Templeton IE, Musib L. MEK inhibitors beyond monotherapy: current and future development. Curr Opin Pharmacol. 2015;23:61\u20137. https:\/\/doi.org\/10.1016\/j.coph.2015.05.012.","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"1520_CR45","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/s1470-2045(19)30027-0","volume":"20","author":"C Eng","year":"2019","unstructured":"Eng C, Kim TW, Bendell J, Argil\u00e9s G, Tebbutt NC, Di Bartolomeo M, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019;20(6):849\u201361. https:\/\/doi.org\/10.1016\/s1470-2045(19)30027-0.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1520_CR46","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/annonc\/mdz113","volume":"30","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Kim TW, Lee CB, Goh BC, Miller WH Jr., Oh DY, et al. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. Ann Oncol. 2019;30(7):1134\u201342. https:\/\/doi.org\/10.1093\/annonc\/mdz113.","journal-title":"Ann Oncol"},{"key":"1520_CR47","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejca.2023.01.023","volume":"184","author":"M Ducreux","year":"2023","unstructured":"Ducreux M, Tabernero J, Grothey A, Arnold D, O\u2019Dwyer PJ, Gilberg F, et al. Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer. Eur J Cancer. 2023;184:137\u201350. https:\/\/doi.org\/10.1016\/j.ejca.2023.01.023.","journal-title":"Eur J Cancer"},{"key":"1520_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005332","author":"B Johnson","year":"2022","unstructured":"Johnson B, Haymaker CL, Parra ER, Soto LMS, Wang X, Thomas JV, et al. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-005332.","journal-title":"J Immunother Cancer"},{"issue":"15_suppl","key":"1520_CR49","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1200\/JCO.2020.38.15_suppl.4031","volume":"38","author":"CH Lieu","year":"2020","unstructured":"Lieu CH, Davis SL, Leong S, Leal AD, Blatchford PJ, Sandhu GS, et al. Results from the safety lead-in for a phase II study of pembrolizumab in combination with binimetinib and bevacizumab in patients with refractory metastatic colorectal cancer (mCRC). J Clin Oncol. 2020;38(15_suppl):4031. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.4031.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1520_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12153-5","volume":"24","author":"E Elez","year":"2024","unstructured":"Elez E, Cubillo A, Alfonso PG, Middleton MR, Chau I, Alkuzweny B, et al. Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b\/2 study. BMC Cancer. 2024;24(1):446. https:\/\/doi.org\/10.1186\/s12885-024-12153-5.","journal-title":"BMC Cancer"},{"key":"1520_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110417","volume":"120","author":"R Guo","year":"2023","unstructured":"Guo R, Li J, Hu J, Fu Q, Yan Y, Xu S, et al. Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: from theory to therapy. Int Immunopharmacol. 2023;120:110417. https:\/\/doi.org\/10.1016\/j.intimp.2023.110417.","journal-title":"Int Immunopharmacol"},{"key":"1520_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116958","volume":"177","author":"KC Huang","year":"2024","unstructured":"Huang KC, Ke TW, Lai CY, Hong WZ, Chang HY, Lee CY, et al. Inhibition of DNMTs increases neoantigen-reactive T-cell toxicity against microsatellite-stable colorectal cancer in combination with radiotherapy. Biomed Pharmacother. 2024;177:116958. https:\/\/doi.org\/10.1016\/j.biopha.2024.116958.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"1520_CR53","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41423-018-0026-y","volume":"16","author":"G Yu","year":"2019","unstructured":"Yu G, Wu Y, Wang W, Xu J, Lv X, Cao X, et al. Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment. Cell Mol Immunol. 2019;16(4):401\u20139. https:\/\/doi.org\/10.1038\/s41423-018-0026-y.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"1520_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02630-w","volume":"9","author":"N Luo","year":"2018","unstructured":"Luo N, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opalenik SR, Li H, et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun. 2018;9(1):248. https:\/\/doi.org\/10.1038\/s41467-017-02630-w.","journal-title":"Nat Commun"},{"key":"1520_CR55","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026831","author":"Y Li","year":"2016","unstructured":"Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016. https:\/\/doi.org\/10.1101\/cshperspect.a026831.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1520_CR56","doi-asserted-by":"publisher","first-page":"S414","DOI":"10.1016\/j.annonc.2023.09.1747","volume":"34","author":"F Wang","year":"2023","unstructured":"Wang F, Jin Y, Luo HY, Guan WL, Li Y, Wang F, et al. 556MO a phase II clinical trial of sintilimab plus chidamide combined with or without bevacizumab in patients with MSS\/pMMR metastatic colorectal cancer. Ann Oncol. 2023;34:S414\u20135. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1747.","journal-title":"Ann Oncol"},{"issue":"12","key":"1520_CR57","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1002\/1878-0261.12953","volume":"15","author":"W Blaszczak","year":"2021","unstructured":"Blaszczak W, Liu G, Zhu H, Barczak W, Shrestha A, Albayrak G, et al. Immune modulation underpins the anti-cancer activity of HDAC inhibitors. Mol Oncol. 2021;15(12):3280\u201398. https:\/\/doi.org\/10.1002\/1878-0261.12953.","journal-title":"Mol Oncol"},{"key":"1520_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-018-0122-2","volume":"6","author":"L Gan","year":"2018","unstructured":"Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 2018;6:10. https:\/\/doi.org\/10.1186\/s40364-018-0122-2.","journal-title":"Biomark Res"},{"key":"1520_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.857808","volume":"13","author":"C Li","year":"2022","unstructured":"Li C, Song J, Guo Z, Gong Y, Zhang T, Huang J, et al. EZH2 inhibitors suppress colorectal cancer by regulating macrophage polarization in the tumor microenvironment. Front Immunol. 2022;13:857808. https:\/\/doi.org\/10.3389\/fimmu.2022.857808.","journal-title":"Front Immunol"},{"issue":"1","key":"1520_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48774-2","volume":"13","author":"K Vejmelkova","year":"2023","unstructured":"Vejmelkova K, Pokorna P, Noskova K, Faustmannova A, Drabova K, Pavelka Z, et al. Tazemetostat in the therapy of pediatric INI1-negative malignant rhabdoid tumors. Sci Rep. 2023;13(1):21623. https:\/\/doi.org\/10.1038\/s41598-023-48774-2.","journal-title":"Sci Rep"},{"issue":"11","key":"1520_CR61","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1158\/1078-0432.CCR-23-1880","volume":"30","author":"R Ciccone","year":"2024","unstructured":"Ciccone R, Quintarelli C, Camera A, Pezzella M, Caruso S, Manni S, et al. GD2-targeting CAR t-cell therapy for patients with GD2+ medulloblastoma. Clin Cancer Res. 2024;30(11):2545\u201357. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1880.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1520_CR62","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.clml.2021.12.014","volume":"22","author":"ML Palomba","year":"2022","unstructured":"Palomba ML, Cartron G, Popplewell L, Ribrag V, Westin J, Huw LY, et al. Combination of atezolizumab and tazemetostat in patients with relapsed\/refractory diffuse large B-cell lymphoma: results from a phase Ib study. Clin Lymphoma Myeloma Leuk. 2022;22(7):504\u201312. https:\/\/doi.org\/10.1016\/j.clml.2021.12.014.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1520_CR63","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003897","author":"L Reppel","year":"2022","unstructured":"Reppel L, Tsahouridis O, Akulian J, Davis IJ, Lee H, Fuca G, et al. Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-003897.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1520_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01733-x","volume":"22","author":"C Xia","year":"2023","unstructured":"Xia C, Yin S, To KKW, Fu L. CD39\/CD73\/A2AR pathway and cancer immunotherapy. Mol Cancer. 2023;22(1):44. https:\/\/doi.org\/10.1186\/s12943-023-01733-x.","journal-title":"Mol Cancer"},{"issue":"6","key":"1520_CR65","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41416-024-02796-3","volume":"131","author":"NH Segal","year":"2024","unstructured":"Segal NH, Tie J, Kopetz S, Ducreux M, Chen E, Dienstmann R, et al. COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer. Br J Cancer. 2024;131(6):1005\u201313. https:\/\/doi.org\/10.1038\/s41416-024-02796-3.","journal-title":"Br J Cancer"},{"issue":"7","key":"1520_CR66","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1007\/s00262-023-03430-6","volume":"72","author":"J Bendell","year":"2023","unstructured":"Bendell J, LoRusso P, Overman M, Noonan AM, Kim DW, Strickler JH, et al. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer Immunol Immunother. 2023;72(7):2443\u201358. https:\/\/doi.org\/10.1007\/s00262-023-03430-6.","journal-title":"Cancer Immunol Immunother"},{"key":"1520_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102106","volume":"62","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Chen G, Chen J, Zhuang L, Du Y, Yu Q, et al. AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. EClinicalMedicine. 2023;62:102106. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102106.","journal-title":"EClinicalMedicine"},{"issue":"2","key":"1520_CR68","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/00313020410001671957","volume":"36","author":"R Karim","year":"2004","unstructured":"Karim R, Tse G, Putti T, Scolyer R, Lee S. The significance of the wnt pathway in the pathology of human cancers. Pathology. 2004;36(2):120\u20138. https:\/\/doi.org\/10.1080\/00313020410001671957.","journal-title":"Pathology"},{"issue":"1","key":"1520_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01892-4","volume":"22","author":"JM Ferreira","year":"2024","unstructured":"Ferreira JM, Gon\u00e7alves CS, Costa BM. Emerging roles and biomarker potential of WNT6 in human cancers. Cell Commun Signal. 2024;22(1):538. https:\/\/doi.org\/10.1186\/s12964-024-01892-4.","journal-title":"Cell Commun Signal"},{"issue":"16_suppl","key":"1520_CR70","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1200\/JCO.2023.41.16_suppl.2601","volume":"41","author":"DSP Tan","year":"2023","unstructured":"Tan DSP, Ng MCH, Subbiah V, Messersmith WA, Strickler JH, Diermayr V, et al. A phase 1B dose escalation study of ETC-159 in combination with pembrolizumab in advanced or metastatic solid tumours. J Clin Oncol. 2023;41(16_suppl):2601. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.2601.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1520_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138. https:\/\/doi.org\/10.1186\/s12943-023-01827-6.","journal-title":"Mol Cancer"},{"issue":"15_suppl","key":"1520_CR72","doi-asserted-by":"publisher","first-page":"TPS4114","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS4114","volume":"38","author":"C Jakubowski","year":"2020","unstructured":"Jakubowski C, Collins NB, Sugar EA, Berg M, Cao H, Giannakis M, et al. A phase I\/II study of PI3Kinase inhibition with copanlisib combined with the anti-PD-1 antibody nivolumab in relapsed\/refractory solid tumors with expansions in MSS colorectal cancer. J Clin Oncol. 2020;38(15_suppl):TPS4114. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.TPS4114.","journal-title":"J Clin Oncol"},{"key":"1520_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02388","volume":"10","author":"Z Urban-Wojciuk","year":"2019","unstructured":"Urban-Wojciuk Z, Khan MM, Oyler BL, F\u00e5hraeus R, Marek-Trzonkowska N, Nita-Lazar A, et al. The role of TLRs in anti-cancer immunity and tumor rejection. Front Immunol. 2019;10:2388. https:\/\/doi.org\/10.3389\/fimmu.2019.02388.","journal-title":"Front Immunol"},{"key":"1520_CR74","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006136","author":"C Lemech","year":"2023","unstructured":"Lemech C, Dredge K, Bampton D, Hammond E, Clouston A, Waterhouse NJ, et al. Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2022-006136.","journal-title":"J Immunother Cancer"},{"issue":"4_suppl","key":"1520_CR75","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1200\/JCO.2023.41.4_suppl.123","volume":"41","author":"YR Lawrence","year":"2023","unstructured":"Lawrence YR, Lieberman S, Redinsky I, Honig N, Shacham-Shmueli E, Halpern N, et al. Combination treatment of intratumoral vidutolimod (CMP-001), radiosurgery, nivolumab, and ipilimumab for metastatic colorectal carcinoma. J Clin Oncol. 2023;41(4_suppl):123. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.123.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1520_CR76","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1158\/1940-6207.Capr-21-0572","volume":"15","author":"J Wei","year":"2022","unstructured":"Wei J, Zhang J, Wang D, Cen B, Lang JD, DuBois RN. The COX-2-PGE2 pathway promotes tumor evasion in colorectal adenomas. Cancer Prev Res Phila. 2022;15(5):285\u201396. https:\/\/doi.org\/10.1158\/1940-6207.Capr-21-0572.","journal-title":"Cancer Prev Res Phila"},{"issue":"12","key":"1520_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153247","volume":"216","author":"V Karpisheh","year":"2020","unstructured":"Karpisheh V, Joshi N, Zekiy AO, Beyzai B, Hojjat-Farsangi M, Namdar A, et al. EP4 receptor as a novel promising therapeutic target in colon cancer. Pathol Res Pract. 2020;216(12):153247. https:\/\/doi.org\/10.1016\/j.prp.2020.153247.","journal-title":"Pathol Res Pract"},{"issue":"8","key":"1520_CR78","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1338239","volume":"6","author":"DI Albu","year":"2017","unstructured":"Albu DI, Wang Z, Huang KC, Wu J, Twine N, Leacu S, et al. EP4 antagonism by E7046 diminishes myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity. Oncoimmunology. 2017;6(8):e1338239. https:\/\/doi.org\/10.1080\/2162402x.2017.1338239.","journal-title":"Oncoimmunology"},{"key":"1520_CR79","doi-asserted-by":"publisher","first-page":"S862","DOI":"10.1016\/j.annonc.2021.08.1414","volume":"32","author":"W Akerley","year":"2021","unstructured":"Akerley W, Reilley M, Marabelle A, Baldini C, Cassier PA, Chisamore M, et al. 1030TiP an open-label multicenter phase Ib study of AN0025, a selective inhibitor of the prostaglandin E2 receptor-type-4 receptor, in combination with pembrolizumab in patients with advanced solid tumors. Ann Oncol. 2021;32:S862\u20133. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1414.","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"1520_CR80","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1200\/JCO.2024.42.16_suppl.3560","volume":"42","author":"F Pietrantonio","year":"2024","unstructured":"Pietrantonio F, Morano F, Niger M, Ghelardi F, Chiodoni C, Palazzo M, et al. Updated results and subgroup analysis by presence of liver metastases of a phase I\/II study of the EP4 antagonist vorbipiprant with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR\/MSS) chemorefractory metastatic colorectal cancer (mCRC). J Clin Oncol. 2024;42(16_suppl):3560. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3560.","journal-title":"J Clin Oncol"},{"key":"1520_CR81","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aak9679","author":"E Allen","year":"2017","unstructured":"Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aak9679.","journal-title":"Sci Transl Med."},{"issue":"12","key":"1520_CR82","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1158\/1078-0432.Ccr-19-2034","volume":"26","author":"A Arina","year":"2020","unstructured":"Arina A, Gutiontov SI, Weichselbaum RR. Radiotherapy and immunotherapy for cancer: from \u201csystemic\u201d to \u201cmultisite.\u201d Clin Cancer Res. 2020;26(12):2777\u201382. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-2034.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1520_CR83","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/1878-0261.12658","volume":"14","author":"M Mondini","year":"2020","unstructured":"Mondini M, Levy A, Meziani L, Milliat F, Deutsch E. Radiotherapy-immunotherapy combinations - perspectives and challenges. Mol Oncol. 2020;14(7):1529\u201337. https:\/\/doi.org\/10.1002\/1878-0261.12658.","journal-title":"Mol Oncol"},{"issue":"5","key":"1520_CR84","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/bjs.11418","volume":"107","author":"END Kok","year":"2020","unstructured":"Kok END, Havenga K, Tanis PJ, de Wilt JHW, Hagendoorn J, Peters FP, et al. Multicentre study of short-course radiotherapy, systemic therapy and resection\/ablation for stage IV rectal cancer. Br J Surg. 2020;107(5):537\u201345. https:\/\/doi.org\/10.1002\/bjs.11418.","journal-title":"Br J Surg"},{"issue":"4_suppl","key":"1520_CR85","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1200\/JCO.2023.41.4_suppl.161","volume":"41","author":"DA Deming","year":"2023","unstructured":"Deming DA, Lubner SJ, Uboha NV, Emmerich P, Kraus S, LoConte NK, et al. Phase Ib of pembrolizumab (pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver oligometastatic MMR-proficient (pMMR) colorectal cancer (CRC): Final results. J Clin Oncol. 2023;41(4_suppl):161. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.161.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1520_CR86","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3760\/cma.j.cn441530-20230107-00010","volume":"26","author":"YQ Wang","year":"2023","unstructured":"Wang YQ, Shen LJ, Wan JF, Zhang H, Wang Y, Wu X, et al. Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH). Zhonghua Wei Chang Wai Ke Za Zhi. 2023;26(5):448\u201358. https:\/\/doi.org\/10.3760\/cma.j.cn441530-20230107-00010.","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"issue":"15_suppl","key":"1520_CR87","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1200\/JCO.2020.38.15_suppl.4100","volume":"38","author":"S Yuki","year":"2020","unstructured":"Yuki S, Bando H, Tsukada Y, Inamori K, Komatsu Y, Homma S, et al. Short-term results of VOLTAGE-A: nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer. J Clin Oncol. 2020;38(15_suppl):4100. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.4100.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1520_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01970-8","volume":"23","author":"A Levy","year":"2024","unstructured":"Levy A, Morel D, Texier M, Sun R, Durand-Labrunie J, Rodriguez-Ruiz ME, et al. An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer. Mol Cancer. 2024;23(1):61. https:\/\/doi.org\/10.1186\/s12943-024-01970-8.","journal-title":"Mol Cancer"},{"issue":"11","key":"1520_CR89","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-025-04185-y","volume":"74","author":"J Yang","year":"2025","unstructured":"Yang J, Zhao X, Xing P, Kong Y, Xu M, Zhang L. Efficacy of PRaG therapy in microsatellite-stable metastatic colorectal cancer: a comparative analysis of PD-1\/PD-L1 inhibitor-based combination therapies. Cancer Immunol Immunother. 2025;74(11):327. https:\/\/doi.org\/10.1007\/s00262-025-04185-y.","journal-title":"Cancer Immunol Immunother"},{"key":"1520_CR90","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1146\/annurev-pathmechdis-031521-041113","volume":"18","author":"JC Sedlak","year":"2023","unstructured":"Sedlak JC, Yilmaz \u00d6H, Roper J. Metabolism and colorectal cancer. Annu Rev Pathol. 2023;18:467\u201392. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-031521-041113.","journal-title":"Annu Rev Pathol"},{"key":"1520_CR91","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003005","author":"DG DeNardo","year":"2021","unstructured":"DeNardo DG, Galkin A, Dupont J, Zhou L, Bendell J. GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-003005.","journal-title":"J Immunother Cancer"},{"issue":"15_suppl","key":"1520_CR92","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1200\/JCO.2021.39.15_suppl.2505","volume":"39","author":"H Park","year":"2021","unstructured":"Park H, Bendell JC, Messersmith WA, Rasco DW, Bono JSD, Strickler JH, et al. Preliminary clinical and biologic results of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab, in advanced solid tumors (KEYNOTE A36). J Clin Oncol. 2021;39(15_suppl):2505. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.2505.","journal-title":"J Clin Oncol"},{"key":"1520_CR93","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001895","author":"C Liu","year":"2021","unstructured":"Liu C, Liu R, Wang B, Lian J, Yao Y, Sun H, et al. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-001895.","journal-title":"J Immunother Cancer"},{"key":"1520_CR94","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejca.2022.03.017","volume":"167","author":"GM Haag","year":"2022","unstructured":"Haag GM, Springfeld C, Gr\u00fcn B, Apostolidis L, Zsch\u00e4bitz S, Dietrich M, et al. Pembrolizumab and maraviroc in refractory mismatch repair proficient\/microsatellite-stable metastatic colorectal cancer - the PICCASSO phase I trial. Eur J Cancer. 2022;167:112\u201322. https:\/\/doi.org\/10.1016\/j.ejca.2022.03.017.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1520_CR95","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.clcc.2024.05.003","volume":"23","author":"A Bessudo","year":"2024","unstructured":"Bessudo A, Haseeb AM, Reeves JA, Zhu X, Wong L, Giranda V, et al. Safety and efficacy of vicriviroc (MK-7690) in combination with pembrolizumab in patients with advanced or metastatic microsatellite stable colorectal cancer. Clin Colorectal Cancer. 2024;23(3):285\u201394. https:\/\/doi.org\/10.1016\/j.clcc.2024.05.003.","journal-title":"Clin Colorectal Cancer"},{"key":"1520_CR96","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005640","author":"C Monge","year":"2023","unstructured":"Monge C, Xie C, Myojin Y, Coffman K, Hrones DM, Wang S, et al. Phase I\/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2022-005640.","journal-title":"J Immunother Cancer"},{"issue":"3_suppl","key":"1520_CR97","doi-asserted-by":"publisher","first-page":"TPS228","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS228","volume":"42","author":"H-J Lenz","year":"2024","unstructured":"Lenz H-J, Somasundaram A, Lee MS, Sohal D, Safyan RA, Zhu M, et al. An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab plus bevacizumab for the treatment of patients with advanced colorectal carcinoma. J Clin Oncol. 2024;42(3_suppl):TPS228. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.TPS228.","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"1520_CR98","doi-asserted-by":"publisher","first-page":"TPS283","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS283","volume":"41","author":"JM Hubbard","year":"2023","unstructured":"Hubbard JM, Ahn DH, Jones JC, Wittenberger K, Molnar L, Lorincz O, et al. Trial in progress: A phase II, multicenter, open-label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301). J Clin Oncol. 2023;41(4_suppl):TPS283. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.TPS283.","journal-title":"J Clin Oncol"},{"issue":"12_Supplement","key":"1520_CR99","doi-asserted-by":"publisher","first-page":"CT570","DOI":"10.1158\/1538-7445.Am2022-ct570","volume":"82","author":"H-J Lenz","year":"2022","unstructured":"Lenz H-J, Koessler T, Oberstein P, Van Cutsem E, Kim S, Fritsch R, et al. Abstract CT570: KISIMA-01: A first-in-human trial of the heterologous prime-boost vaccine ATP128\/VSV-GP128 with ezabenlimab (BI 754091) in patients with stage IV colorectal cancer. Cancer Res. 2022;82(12_Supplement):CT570. https:\/\/doi.org\/10.1158\/1538-7445.Am2022-ct570.","journal-title":"Cancer Res"},{"issue":"11","key":"1520_CR100","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598\u2013608. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0386.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1520_CR101","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1158\/2159-8290.CD-21-0450","volume":"12","author":"CF Friedman","year":"2022","unstructured":"Friedman CF, Hainsworth JD, Kurzrock R, Spigel DR, Burris HA, Sweeney CJ, et al. Atezolizumab treatment of tumors with high tumor mutational burden from MyPathway, a multicenter, open-label, phase IIa multiple basket study. Cancer Discov. 2022;12(3):654\u201369. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0450.","journal-title":"Cancer Discov"},{"key":"1520_CR102","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00267","volume":"6","author":"B Garmezy","year":"2022","unstructured":"Garmezy B, Gheeya J, Lin HY, Huang Y, Kim T, Jiang X, et al. Clinical and molecular characterization of POLE mutations as predictive biomarkers of response to immune checkpoint inhibitors in advanced cancers. JCO Precis Oncol. 2022;6:e2100267. https:\/\/doi.org\/10.1200\/PO.21.00267.","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"1520_CR103","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1001\/jamaoncol.2019.2963","volume":"5","author":"F Wang","year":"2019","unstructured":"Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, et al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol. 2019;5(10):1504\u20136. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2963.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1520_CR104","doi-asserted-by":"publisher","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","volume":"143","author":"K Kulangara","year":"2019","unstructured":"Kulangara K, Zhang N, Corigliano E, Guerrero L, Waldroup S, Jaiswal D, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019;143(3):330\u20137. https:\/\/doi.org\/10.5858\/arpa.2018-0043-OA.","journal-title":"Arch Pathol Lab Med"},{"key":"1520_CR105","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000842","author":"AS Laino","year":"2020","unstructured":"Laino AS, Woods D, Vassallo M, Qian X, Tang H, Wind-Rotolo M, et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-000842.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"1520_CR106","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202201982RRR","volume":"37","author":"Y Shao","year":"2023","unstructured":"Shao Y, Lan Y, Chai X, Gao S, Zheng J, Huang R, et al. CXCL8 induces M2 macrophage polarization and inhibits CD8(+) T cell infiltration to generate an immunosuppressive microenvironment in colorectal cancer. FASEB J. 2023;37(10):e23173. https:\/\/doi.org\/10.1096\/fj.202201982RRR.","journal-title":"FASEB J"},{"issue":"1","key":"1520_CR107","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","volume":"8","author":"F Bertrand","year":"2017","unstructured":"Bertrand F, Montfort A, Marcheteau E, Imbert C, Gilhodes J, Filleron T, et al. TNFalpha blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun. 2017;8(1):2256. https:\/\/doi.org\/10.1038\/s41467-017-02358-7.","journal-title":"Nat Commun"},{"issue":"6","key":"1520_CR108","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.21037\/jgo-23-931","volume":"14","author":"X Yang","year":"2023","unstructured":"Yang X, Yin X, Qu X, Guo G, Zeng Y, Liu W, et al. Efficacy, safety, and predictors of fruquintinib plus anti-programmed death receptor-1 (PD-1) antibody in refractory microsatellite stable metastatic colorectal cancer in a real-world setting: a retrospective cohort study. J Gastrointest Oncol. 2023;14(6):2425\u201335. https:\/\/doi.org\/10.21037\/jgo-23-931.","journal-title":"J Gastrointest Oncol"},{"key":"1520_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102418","author":"X Zeng","year":"2021","unstructured":"Zeng X, Ward SE, Zhou J, Cheng ASL. Liver immune microenvironment and metastasis from colorectal cancer-pathogenesis and therapeutic perspectives. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13102418.","journal-title":"Cancers (Basel)"},{"key":"1520_CR110","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-24-4916","author":"S Liu","year":"2025","unstructured":"Liu S, Zhang Z, Wang Z, Liu C, Liang G, Xu T, et al. SPP1 drives colorectal cancer liver metastasis and immunotherapy resistance by stimulating CXCL12 production in cancer-associated fibroblasts. Cancer Res. 2025. https:\/\/doi.org\/10.1158\/0008-5472.Can-24-4916.","journal-title":"Cancer Res"},{"issue":"10","key":"1520_CR111","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1007\/s00432-021-03708-1","volume":"147","author":"F Cao","year":"2021","unstructured":"Cao F, Zheng J, Luo J, Zhang Z, Shao G. Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens. J Cancer Res Clin Oncol. 2021;147(10):2993\u20133002. https:\/\/doi.org\/10.1007\/s00432-021-03708-1.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"16_suppl","key":"1520_CR112","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1200\/JCO.2023.41.16_suppl.3585","volume":"41","author":"A Feng","year":"2023","unstructured":"Feng A, Gao S, Guo J, Kou F, Liu S, Zhang X, et al. Efficacy and safety of irinotecan-eluting HepaSphere transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for unresectable colorectal liver metastases. J Clin Oncol. 2023;41(16_suppl):3585. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.3585.","journal-title":"J Clin Oncol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01520-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01520-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01520-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:29:41Z","timestamp":1783160981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01520-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":112,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1520"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01520-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"No datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"LYZ provided initial draft preparation and editing. LYZ and LY jointly conceptualize the research concept. ZLC and LY review and edit the manuscript. We declare that all authors have read and approved the final version and agree to take responsibility for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s contributions"}}]}}